HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy

被引：0
|
作者：
Catalina Falo
Abelardo Moreno
Mar Varela
Belen Lloveras
Agnès Figueras
Agustín Escobedo
机构：
[1] Hospital Duran i Reynals,Breast Cancer Unit, Institut Català d’Oncologia
[2] Hospital Universitari de Bellvitge,Department of Medical Oncology, Breast Cancer Unit, Institut Català d’Oncologia
[3] Hospital Duran i Reynals,Department of Pathology, Breast Cancer Unit
[4] Hospital Universitari de Bellvitge,Tumour Bank, Institut Català d’Oncologia
[5] Hospital Duran i Reynals,Department of Pathology, Institut Català d’Oncologia
[6] Hospital Duran i Reynals,Translational Research Laboratory, Institut Català d’Oncologia
[7] Hospital Duran i Reynals,Breast Cancer Unit, Institut Català d’Oncologia
[8] Hospital Duran i Reynals,Unitat Funcional de Mama
[9] Institut Català d’Oncologia,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2007年 / 133卷
关键词：
Breast carcinoma; Her-2/; Primary chemotherapy; Response; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：423 / 429
页数：6
相关论文
共 50 条
  • [21] Comparative assays for the HER-2/neu oncogene status in breast cancer
    Vera-Román, JM
    Rubio-Martínez, LA
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2004, 128 (06) : 627 - 633
  • [22] Status of estrogen, progesterone and her-2/neu receptors in breast cancer
    Lumturije, G.
    Kushtrim, S. H.
    Rame, A.
    Adriatik, K.
    Esat, B.
    Ardita, K.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2010, 15 : 87 - 87
  • [23] HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma
    Learn, PA
    Yeh, IT
    McNutt, M
    Chisholm, GB
    Pollock, BH
    Rousseau, DL
    Sharkey, FE
    Cruz, AB
    Kahlenberg, MS
    CANCER, 2005, 103 (11) : 2252 - 2260
  • [24] Her-2/neu and topoisomerase IIaexpression in primary and metastatic breast cancer
    Cardoso F.
    Breast Cancer Research, 3 (1)
  • [25] HER-2/neu diagnostics in breast cancer
    Carney, Walter P.
    Leitzel, Kim
    Ali, Suhail
    Neumann, Rainer
    Lipton, Allan
    BREAST CANCER RESEARCH, 2007, 9 (03)
  • [26] CMF plus radiotherapy in the primary treatment of operable breast cancer: Preliminary results of a phase II pilot study
    Bellantone, R
    Lombardi, CP
    Cefaro, GA
    Nardone, L
    Rossi, S
    Minelli, S
    Raffaelli, M
    Crucitti, F
    JOURNAL OF SURGICAL ONCOLOGY, 1998, 68 (01) : 48 - 50
  • [27] HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy
    Pectasides, D
    Gaglia, A
    Arapantoni-Dadioti, P
    Bobota, A
    Valavanis, C
    Kostopoulou, V
    Mylonakis, N
    Karabelis, A
    Pectasides, M
    Economopoulos, T
    ANTICANCER RESEARCH, 2006, 26 (1B) : 647 - 653
  • [28] Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy
    Mark D. Pegram
    Giovanni Pauletti
    Dennis J. Slamon
    Breast Cancer Research and Treatment, 1998, 52 : 65 - 77
  • [29] HER-2/neu as a predictive marker of response to breast cancer therapy
    Pegram, MD
    Pauletti, G
    Slamon, DJ
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) : 65 - 77
  • [30] High pathologic complete response after primary chemotherapy in patients treated with weekly paclitaxel followed by FEC chemotherapy with simultaneous trastuzumab in Her-2 positive operable breast cancer
    Pernas, S.
    Gil Gil, M.
    Urruticoechea, A.
    Fernandez-Ortega, A.
    Falo, C.
    Piulats, J. M.
    Prieto, L.
    Pla, M. J.
    Moreno, A.
    Germa, J. R.
    ANNALS OF ONCOLOGY, 2006, 17 : 96 - 96
12345